Eli Lilly and Company
Olumiant is a once-daily prescription medication for adults with moderately to severely active rheumatoid arthritis.
The pharmaceutical agent is designed for people with whom a TNH inhibitor did not work. It modulated the signaling pathway at the point of Janus kinase inhibitors to prevent the phosphorylation and activation of STATs.
Common side effects of Oluminat include upper respiratory tract infections, nausea, cold sores and shingles.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tell Us What You Think!
You must be logged in to post a comment.